Skip to main content
Top
Published in: Current Diabetes Reports 4/2012

01-08-2012 | Microvascular Complications—Retinopathy (JK Sun, Section Editor)

Current Epidemiology of Diabetic Retinopathy and Diabetic Macular Edema

Authors: Jie Ding, Tien Yin Wong

Published in: Current Diabetes Reports | Issue 4/2012

Login to get access

Abstract

With increasing global prevalence of diabetes, diabetic retinopathy (DR) is set to be the principle cause of vision impairment in many countries. DR affects a third of people with diabetes and the prevalence increases with duration of diabetes, hyperglycemia, and hypertension—the major risk factors for the onset and progression of DR. There are now increasing data on the epidemiology of diabetic macular edema (DME), an advanced complication of DR, with studies suggesting DME may affect up to 7 % of people with diabetes. The risk factors for DME are largely similar to DR, but dyslipidemia appears to play a more significant role. Early detection of DR and DME through screening programs and appropriate referral for therapy is important to preserve vision in individuals with diabetes. Future research is necessary to better understand the potential role of other risk factors such as apolipoproteins and genetic predisposition to shape public health programs.
Literature
1.
go back to reference Cheung N, Mitchell P, Wong TY. Diabetic retinopathy. Lancet. 2010;10(376):124–36.CrossRef Cheung N, Mitchell P, Wong TY. Diabetic retinopathy. Lancet. 2010;10(376):124–36.CrossRef
2.
go back to reference • Yau JW, Rogers SL, Kawasaki R, et al. Global prevalence and major risk factors of diabetic retinopathy. Diabetes Care. 2012;35:556–64. A meta-analysis of individual participant data on the prevalence and major risk factors of diabetic retinopathy.PubMedCrossRef • Yau JW, Rogers SL, Kawasaki R, et al. Global prevalence and major risk factors of diabetic retinopathy. Diabetes Care. 2012;35:556–64. A meta-analysis of individual participant data on the prevalence and major risk factors of diabetic retinopathy.PubMedCrossRef
3.
go back to reference Simó R, Hernández C. Advances in the medical treatment of diabetic retinopathy. Diabetes Care. 2009;32:1556–62.PubMedCrossRef Simó R, Hernández C. Advances in the medical treatment of diabetic retinopathy. Diabetes Care. 2009;32:1556–62.PubMedCrossRef
4.
go back to reference Zhang X, Saaddine JB, Chou CF, et al. Prevalence of diabetic retinopathy in the United States, 2005–2008. JAMA. 2010;304:649–56.PubMedCrossRef Zhang X, Saaddine JB, Chou CF, et al. Prevalence of diabetic retinopathy in the United States, 2005–2008. JAMA. 2010;304:649–56.PubMedCrossRef
5.
go back to reference Tapp RJ, Shaw JE, Harper CA, et al. The prevalence of and factors associated with diabetic retinopathy in the Australian population. Diabetes Care. 2003;26:1731–37.PubMedCrossRef Tapp RJ, Shaw JE, Harper CA, et al. The prevalence of and factors associated with diabetic retinopathy in the Australian population. Diabetes Care. 2003;26:1731–37.PubMedCrossRef
6.
go back to reference Raymond NT, Varadhan L, Reynold DR, et al. Higher prevalence of retinopathy in diabetic patients of South Asian ethnicity compared with white Europeans in the community: a cross-sectional study. Diabetes Care. 2009;32:410–15.PubMedCrossRef Raymond NT, Varadhan L, Reynold DR, et al. Higher prevalence of retinopathy in diabetic patients of South Asian ethnicity compared with white Europeans in the community: a cross-sectional study. Diabetes Care. 2009;32:410–15.PubMedCrossRef
7.
go back to reference Wang FH, Liang YB, Zhang F, et al. Prevalence of diabetic retinopathy in rural China: the Handan Eye Study. Ophthalmology. 2009;116:461–67.PubMedCrossRef Wang FH, Liang YB, Zhang F, et al. Prevalence of diabetic retinopathy in rural China: the Handan Eye Study. Ophthalmology. 2009;116:461–67.PubMedCrossRef
8.
go back to reference Xie XW, Xu L, Wang YX, Jonas JB. Prevalence and associated factors of diabetic retinopathy. The Beijing Eye Study 2006. Graefes Arch Clin Exp Ophthalmol. 2008;246:1519–26.PubMedCrossRef Xie XW, Xu L, Wang YX, Jonas JB. Prevalence and associated factors of diabetic retinopathy. The Beijing Eye Study 2006. Graefes Arch Clin Exp Ophthalmol. 2008;246:1519–26.PubMedCrossRef
9.
go back to reference Wong TY, Cheung N, Tay WT, et al. Prevalence and risk factors for diabetic retinopathy: the Singapore Malay EyeStudy. Ophthalmology. 2008;115:1869–75.PubMedCrossRef Wong TY, Cheung N, Tay WT, et al. Prevalence and risk factors for diabetic retinopathy: the Singapore Malay EyeStudy. Ophthalmology. 2008;115:1869–75.PubMedCrossRef
10.
go back to reference Rema M, Premkumar S, Anitha B, et al. Prevalence of diabetic retinopathy in urban India: the Chennai Urban Rural Epidemiology Study (CURES) eye study, I. Invest Ophthalmol Vis Sci. 2005;46:2328–33.PubMedCrossRef Rema M, Premkumar S, Anitha B, et al. Prevalence of diabetic retinopathy in urban India: the Chennai Urban Rural Epidemiology Study (CURES) eye study, I. Invest Ophthalmol Vis Sci. 2005;46:2328–33.PubMedCrossRef
11.
go back to reference Chen L, Magliano DJ, Zimmet PZ. The worldwide epidemiology of type 2 diabetes mellitus-present and future perspectives. Nat Rev Endocrinol. 2011;8:228–36.PubMedCrossRef Chen L, Magliano DJ, Zimmet PZ. The worldwide epidemiology of type 2 diabetes mellitus-present and future perspectives. Nat Rev Endocrinol. 2011;8:228–36.PubMedCrossRef
12.
go back to reference Klein R. The epidemiology of diabetic retinopathy. In: Duh E, editor. Diabetic retinopathy. Totowa: Humana Press; 2008. p. 67–108.CrossRef Klein R. The epidemiology of diabetic retinopathy. In: Duh E, editor. Diabetic retinopathy. Totowa: Humana Press; 2008. p. 67–108.CrossRef
13.
go back to reference Klein R, Klein BE, Moss SE, Cruickshanks KJ. The Wisconsin Epidemiologic Study of Diabetic Retinopathy. XV. The long-term incidence of macular edema. Ophthalmology. 1995;102:7–16.PubMed Klein R, Klein BE, Moss SE, Cruickshanks KJ. The Wisconsin Epidemiologic Study of Diabetic Retinopathy. XV. The long-term incidence of macular edema. Ophthalmology. 1995;102:7–16.PubMed
14.
go back to reference Klein R, Knudtson MD, Lee KE, Gangnon R, Klein BE. The Wisconsin Epidemiologic Study of Diabetic Retinopathy: XXII the twenty-five-year progression of retinopathy in persons with type 1 diabetes. Ophthalmology. 2008;115:1859–68.PubMedCrossRef Klein R, Knudtson MD, Lee KE, Gangnon R, Klein BE. The Wisconsin Epidemiologic Study of Diabetic Retinopathy: XXII the twenty-five-year progression of retinopathy in persons with type 1 diabetes. Ophthalmology. 2008;115:1859–68.PubMedCrossRef
15.
go back to reference Klein R, Knudtson MD, Lee KE, Gangnon R, Klein BE. The Wisconsin Epidemiologic Study of Diabetic Retinopathy XXIII: the twenty-five-year incidence of macular edema in persons with type 1 diabetes. Ophthalmology. 2009;116:497–503.PubMedCrossRef Klein R, Knudtson MD, Lee KE, Gangnon R, Klein BE. The Wisconsin Epidemiologic Study of Diabetic Retinopathy XXIII: the twenty-five-year incidence of macular edema in persons with type 1 diabetes. Ophthalmology. 2009;116:497–503.PubMedCrossRef
16.
go back to reference Jones CD, Greenwood RH, Misra A, Bachmann MO. Incidence and progression of diabetic retinopathy during 17 years of a population-based screening program in England. Diabetes Care. 2012;35:592–96.PubMedCrossRef Jones CD, Greenwood RH, Misra A, Bachmann MO. Incidence and progression of diabetic retinopathy during 17 years of a population-based screening program in England. Diabetes Care. 2012;35:592–96.PubMedCrossRef
17.
go back to reference Klein R, Klein BE. Are individuals with diabetes seeing better? A long-term epidemiological perspective. Diabetes. 2010;59:1853–60.PubMedCrossRef Klein R, Klein BE. Are individuals with diabetes seeing better? A long-term epidemiological perspective. Diabetes. 2010;59:1853–60.PubMedCrossRef
18.
go back to reference Lecaire T, Palta M, Zhang H, et al. Lower-than-expected prevalence and severity of retinopathy in an incident cohort followed during the first 4–14 years of type 1 diabetes: the Wisconsin Diabetes Registry Study. Am J Epidemiol. 2006;164:143–50.PubMedCrossRef Lecaire T, Palta M, Zhang H, et al. Lower-than-expected prevalence and severity of retinopathy in an incident cohort followed during the first 4–14 years of type 1 diabetes: the Wisconsin Diabetes Registry Study. Am J Epidemiol. 2006;164:143–50.PubMedCrossRef
19.
go back to reference Cugati S, Kifley A, Mitchell P, Wang JJ. Temporal trends in the age-specific prevalence of diabetes and diabetic retinopathy in older persons: Population-based survey findings. Diabetes Res Clin Pract. 2006;74:301–8.PubMedCrossRef Cugati S, Kifley A, Mitchell P, Wang JJ. Temporal trends in the age-specific prevalence of diabetes and diabetic retinopathy in older persons: Population-based survey findings. Diabetes Res Clin Pract. 2006;74:301–8.PubMedCrossRef
20.
go back to reference Harris MI, Klein R, Cowie CC, Rowland M, Byrd-Holt DD. Is the risk of diabetic retinopathy greater in non-Hispanic blacks and Mexican Americans than in non-Hispanic whites with type 2 diabetes? A U.S. population study. Diabetes Care. 1998;21:1230–5.PubMedCrossRef Harris MI, Klein R, Cowie CC, Rowland M, Byrd-Holt DD. Is the risk of diabetic retinopathy greater in non-Hispanic blacks and Mexican Americans than in non-Hispanic whites with type 2 diabetes? A U.S. population study. Diabetes Care. 1998;21:1230–5.PubMedCrossRef
21.
go back to reference Olsen BS, Sjølie AK, Hougaard P, et al. The significance of the prepubertal diabetes duration for the development of retinopathy and nephropathy in patients with type 1 diabetes. J Diabetes Complications. 2004;18:160–4.PubMedCrossRef Olsen BS, Sjølie AK, Hougaard P, et al. The significance of the prepubertal diabetes duration for the development of retinopathy and nephropathy in patients with type 1 diabetes. J Diabetes Complications. 2004;18:160–4.PubMedCrossRef
22.
go back to reference Donaghue KC, Fairchild JM, Craig ME, et al. Do all prepubertal years of diabetes duration contribute equally to diabetic complications? Diabetes Care. 2003;26:1224–9.PubMedCrossRef Donaghue KC, Fairchild JM, Craig ME, et al. Do all prepubertal years of diabetes duration contribute equally to diabetic complications? Diabetes Care. 2003;26:1224–9.PubMedCrossRef
23.
go back to reference Klein BE, Moss SE, Klein R. Is menarche associated with diabetic retinopathy? Diabetes Care. 1990;13:1034–38.PubMedCrossRef Klein BE, Moss SE, Klein R. Is menarche associated with diabetic retinopathy? Diabetes Care. 1990;13:1034–38.PubMedCrossRef
24.
go back to reference Sultan MB, Starita C, Huang K. Epidemiology, risk factors and management of paediatric diabetic retinopathy. Br J Ophthalmol. 2012;96:312–7.PubMedCrossRef Sultan MB, Starita C, Huang K. Epidemiology, risk factors and management of paediatric diabetic retinopathy. Br J Ophthalmol. 2012;96:312–7.PubMedCrossRef
25.
go back to reference Vestgaard M, Ringholm L, Laugesen CS, et al. Pregnancy-induced sight-threatening diabetic retinopathy in women with Type 1 diabetes. Diabet Med. 2010;27:431–5.PubMedCrossRef Vestgaard M, Ringholm L, Laugesen CS, et al. Pregnancy-induced sight-threatening diabetic retinopathy in women with Type 1 diabetes. Diabet Med. 2010;27:431–5.PubMedCrossRef
26.
go back to reference Rasmussen KL, Laugesen CS, Ringholm L, et al. Progression of diabetic retinopathy during pregnancy in women with type 2 diabetes. Diabetologia. 2010;53:1076–83.PubMedCrossRef Rasmussen KL, Laugesen CS, Ringholm L, et al. Progression of diabetic retinopathy during pregnancy in women with type 2 diabetes. Diabetologia. 2010;53:1076–83.PubMedCrossRef
27.
go back to reference Sheth BP. Does pregnancy accelerate the rate of progression of diabetic retinopathy? An update. Curr Diab Rep. 2008;8:270–3.PubMedCrossRef Sheth BP. Does pregnancy accelerate the rate of progression of diabetic retinopathy? An update. Curr Diab Rep. 2008;8:270–3.PubMedCrossRef
28.
go back to reference The Diabetes Control and Complications Trial Research Group. Effect of pregnancy on microvascular complications in the Diabetes Control and Complications Trial. Diabetes Care. 2000;23:1084–91.CrossRef The Diabetes Control and Complications Trial Research Group. Effect of pregnancy on microvascular complications in the Diabetes Control and Complications Trial. Diabetes Care. 2000;23:1084–91.CrossRef
29.
go back to reference Chew EY, Mills JL, Metzger BE, et al. Metabolic control and progression of retinopathy. The Diabetes in Early Pregnancy Study. National Institute of Child Health and Human Development Diabetes in Early Pregnancy Study. Diabetes Care. 1995;18:631–37.PubMedCrossRef Chew EY, Mills JL, Metzger BE, et al. Metabolic control and progression of retinopathy. The Diabetes in Early Pregnancy Study. National Institute of Child Health and Human Development Diabetes in Early Pregnancy Study. Diabetes Care. 1995;18:631–37.PubMedCrossRef
30.
go back to reference Mohamed Q, Gillies MC, Wong TY. Management of diabetic retinopathy: a systematic review. JAMA. 2007;298:902–16.PubMedCrossRef Mohamed Q, Gillies MC, Wong TY. Management of diabetic retinopathy: a systematic review. JAMA. 2007;298:902–16.PubMedCrossRef
31.
go back to reference The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med. 1993;329:977–86.CrossRef The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med. 1993;329:977–86.CrossRef
32.
go back to reference The Diabetes Control and ComplicationsTrial/Epidemiology of Diabetes Interventions and Complications Research Group. Retinopathy and nephropathy in patients with type 1 diabetes four years after a trial of intensive therapy. N Engl J Med. 2000;342:381–9.CrossRef The Diabetes Control and ComplicationsTrial/Epidemiology of Diabetes Interventions and Complications Research Group. Retinopathy and nephropathy in patients with type 1 diabetes four years after a trial of intensive therapy. N Engl J Med. 2000;342:381–9.CrossRef
33.
go back to reference Early worsening of diabetic retinopathy in the Diabetes Control and Complications Trial. Arch Ophthalmol. 1998;116:874–86. Early worsening of diabetic retinopathy in the Diabetes Control and Complications Trial. Arch Ophthalmol. 1998;116:874–86.
34.
go back to reference White NH, Sun W, Cleary PA, et al. Prolonged effect of intensive therapy on the risk of retinopathy complications in patients with type 1 diabetes mellitus: 10 years after the Diabetes Control and Complications Trial. Arch Ophthalmol. 2008;126:1707–15.PubMedCrossRef White NH, Sun W, Cleary PA, et al. Prolonged effect of intensive therapy on the risk of retinopathy complications in patients with type 1 diabetes mellitus: 10 years after the Diabetes Control and Complications Trial. Arch Ophthalmol. 2008;126:1707–15.PubMedCrossRef
35.
go back to reference Wong TY, Liew G, Tapp RJ. Relation between fasting glucose and retinopathy for diagnosis of diabetes: three population-based cross-sectional studies. Lancet. 2008;371:736–43.PubMedCrossRef Wong TY, Liew G, Tapp RJ. Relation between fasting glucose and retinopathy for diagnosis of diabetes: three population-based cross-sectional studies. Lancet. 2008;371:736–43.PubMedCrossRef
36.
go back to reference Patel A, MacMahon S, Chalmers J, et al. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med. 2008;358:2560–72.PubMedCrossRef Patel A, MacMahon S, Chalmers J, et al. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med. 2008;358:2560–72.PubMedCrossRef
37.
go back to reference Gerstein HC, Miller ME, Byington RP, et al. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med. 2008;358:2545–59.PubMedCrossRef Gerstein HC, Miller ME, Byington RP, et al. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med. 2008;358:2545–59.PubMedCrossRef
38.
39.
go back to reference Duckworth W, Abraira C, Moritz T, et al. Glucose control and vascular complications in veterans with type 2 diabetes. N Engl J Med. 2009;360:129–39.PubMedCrossRef Duckworth W, Abraira C, Moritz T, et al. Glucose control and vascular complications in veterans with type 2 diabetes. N Engl J Med. 2009;360:129–39.PubMedCrossRef
40.
go back to reference Gallego PH, Craig ME, Hing S, Donaghue KC. Role of blood pressure in development of early retinopathy in adolescents with type 1 diabetes: prospective cohort study. BMJ. 2008;337:a918.PubMedCrossRef Gallego PH, Craig ME, Hing S, Donaghue KC. Role of blood pressure in development of early retinopathy in adolescents with type 1 diabetes: prospective cohort study. BMJ. 2008;337:a918.PubMedCrossRef
41.
go back to reference Holman RR, Paul SK, Bethel MA, Neil HA, Matthews DR. Long-term follow-up after tight control of blood pressure in type 2 diabetes. N Engl J Med. 2008;359:1565–76.PubMedCrossRef Holman RR, Paul SK, Bethel MA, Neil HA, Matthews DR. Long-term follow-up after tight control of blood pressure in type 2 diabetes. N Engl J Med. 2008;359:1565–76.PubMedCrossRef
42.
43.
go back to reference Chaturvedi N, Porta M, Klein R, et al. Effect of candesartan on prevention (DIRECT-Prevent 1) and progression (DIRECT-Protect 1) of retinopathy in type 1 diabetes: randomised, placebo-controlled trials. Lancet. 2008;372:1394–402.PubMedCrossRef Chaturvedi N, Porta M, Klein R, et al. Effect of candesartan on prevention (DIRECT-Prevent 1) and progression (DIRECT-Protect 1) of retinopathy in type 1 diabetes: randomised, placebo-controlled trials. Lancet. 2008;372:1394–402.PubMedCrossRef
44.
go back to reference Sjolie AK, Klein R, Porta M, et al. Effect of candesartan on progression and regression of retinopathy in type 2 diabetes (DIRECT-Protect 2): a randomised placebo-controlled trial. Lancet. 2008;372:1385–93.PubMedCrossRef Sjolie AK, Klein R, Porta M, et al. Effect of candesartan on progression and regression of retinopathy in type 2 diabetes (DIRECT-Protect 2): a randomised placebo-controlled trial. Lancet. 2008;372:1385–93.PubMedCrossRef
45.
go back to reference Mauer M, Zinman B, Gardiner R, et al. Renal and retinal effects of enalapril and losartan in type 1 diabetes. N Engl J Med. 2009;361:40–51.PubMedCrossRef Mauer M, Zinman B, Gardiner R, et al. Renal and retinal effects of enalapril and losartan in type 1 diabetes. N Engl J Med. 2009;361:40–51.PubMedCrossRef
46.
go back to reference Raman R, Rani PK, Kulothungan V. Influence of serum lipids on clinically significant versus nonclinically significant macular edema: SN-DREAMS Report number 13. Ophthalmology. 2010;117:766–72.PubMedCrossRef Raman R, Rani PK, Kulothungan V. Influence of serum lipids on clinically significant versus nonclinically significant macular edema: SN-DREAMS Report number 13. Ophthalmology. 2010;117:766–72.PubMedCrossRef
47.
go back to reference Rema M, Srivastava BK, Anitha B, et al. Association of serum lipids with diabetic retinopathy in urban South Indians—the Chennai Urban Rural Epidemiology Study (CURES) Eye Study—2. Diabet Med. 2006;23:1029–36.PubMedCrossRef Rema M, Srivastava BK, Anitha B, et al. Association of serum lipids with diabetic retinopathy in urban South Indians—the Chennai Urban Rural Epidemiology Study (CURES) Eye Study—2. Diabet Med. 2006;23:1029–36.PubMedCrossRef
48.
go back to reference Lyons TJ, Jenkins AJ, Zheng D, et al. Diabetic retinopathy and serum lipoprotein subclasses in the DCCT/EDIC cohort. Invest Ophthalmol Vis Sci. 2004;45:910–18.PubMedCrossRef Lyons TJ, Jenkins AJ, Zheng D, et al. Diabetic retinopathy and serum lipoprotein subclasses in the DCCT/EDIC cohort. Invest Ophthalmol Vis Sci. 2004;45:910–18.PubMedCrossRef
49.
go back to reference Wong TY, Klein R, Islam FM, et al. Diabetic retinopathy in a multi-ethnic cohort in the United States. Am J Ophthalmol. 2006;141:446–55.PubMedCrossRef Wong TY, Klein R, Islam FM, et al. Diabetic retinopathy in a multi-ethnic cohort in the United States. Am J Ophthalmol. 2006;141:446–55.PubMedCrossRef
50.
go back to reference Benarous R, Sasongko MB, Qureshi S, et al. Differential association of serum lipids with diabetic retinopathy and diabeticmacular edema. Invest Ophthalmol Vis Sci. 2011;52:7464–9.PubMedCrossRef Benarous R, Sasongko MB, Qureshi S, et al. Differential association of serum lipids with diabetic retinopathy and diabeticmacular edema. Invest Ophthalmol Vis Sci. 2011;52:7464–9.PubMedCrossRef
51.
go back to reference Keech AC, Mitchell P, Summanen PA, et al. Effect of fenofibrate on the need for laser treatment for diabetic retinopathy (FIELD study): a randomised controlled trial. Lancet. 2007;370:1687–97.PubMedCrossRef Keech AC, Mitchell P, Summanen PA, et al. Effect of fenofibrate on the need for laser treatment for diabetic retinopathy (FIELD study): a randomised controlled trial. Lancet. 2007;370:1687–97.PubMedCrossRef
52.
go back to reference Chew EY, Ambrosius WT, Davis MD, et al. Effects of medical therapies on retinopathy progression in type 2 diabetes. N Engl J Med. 2010;363:233–44.PubMedCrossRef Chew EY, Ambrosius WT, Davis MD, et al. Effects of medical therapies on retinopathy progression in type 2 diabetes. N Engl J Med. 2010;363:233–44.PubMedCrossRef
55.
go back to reference Dirani M, Xie J, Fenwick E, et al. Are obesity and anthropometry risk factors for diabetic retinopathy? The diabetes management project. Invest Ophthalmol Vis Sci. 2011;52:4416–21.PubMedCrossRef Dirani M, Xie J, Fenwick E, et al. Are obesity and anthropometry risk factors for diabetic retinopathy? The diabetes management project. Invest Ophthalmol Vis Sci. 2011;52:4416–21.PubMedCrossRef
56.
go back to reference Chaturvedi N, Sjoelie AK, Porta M. Markers of insulin resistance are strong risk factors for retinopathy incidence in type 1 diabetes. Diabetes Care. 2001;24:284–9.PubMedCrossRef Chaturvedi N, Sjoelie AK, Porta M. Markers of insulin resistance are strong risk factors for retinopathy incidence in type 1 diabetes. Diabetes Care. 2001;24:284–9.PubMedCrossRef
57.
go back to reference Henricsson M, Nyström L, Blohmé G. The incidence of retinopathy 10 years after diagnosis in young adult people with diabetes: results from the nationwide population-based Diabetes Incidence Study in Sweden (DISS). Diabetes Care. 2003;26:349–54. 83.PubMedCrossRef Henricsson M, Nyström L, Blohmé G. The incidence of retinopathy 10 years after diagnosis in young adult people with diabetes: results from the nationwide population-based Diabetes Incidence Study in Sweden (DISS). Diabetes Care. 2003;26:349–54. 83.PubMedCrossRef
58.
go back to reference Klein R, Klein BE, Moss SE, Davis MD, DeMets DL. The Wisconsin epidemiologic study of diabetic retinopathy. III. Prevalence and risk of diabetic retinopathy when age at diagnosis is 30 or more years. Arch Ophthalmol. 1984;102:527–32.PubMedCrossRef Klein R, Klein BE, Moss SE, Davis MD, DeMets DL. The Wisconsin epidemiologic study of diabetic retinopathy. III. Prevalence and risk of diabetic retinopathy when age at diagnosis is 30 or more years. Arch Ophthalmol. 1984;102:527–32.PubMedCrossRef
59.
go back to reference Lim LS, Tai ES, Mitchell P, et al. C-reactive protein, body mass index, and diabetic retinopathy. Invest Ophthalmol Vis Sci. 2010;51:4458–63.PubMedCrossRef Lim LS, Tai ES, Mitchell P, et al. C-reactive protein, body mass index, and diabetic retinopathy. Invest Ophthalmol Vis Sci. 2010;51:4458–63.PubMedCrossRef
60.
go back to reference Klein R, Klein BE, Moss SE. Is obesity related to microvascular and macrovascular complications in diabetes? The Wisconsin Epidemiologic Study of Diabetic Retinopathy. Arch Intern Med. 1997;157:650–6.PubMedCrossRef Klein R, Klein BE, Moss SE. Is obesity related to microvascular and macrovascular complications in diabetes? The Wisconsin Epidemiologic Study of Diabetic Retinopathy. Arch Intern Med. 1997;157:650–6.PubMedCrossRef
61.
go back to reference Lyons TJ, Jenkins AJ, Zheng D, et al. Diabetic retinopathy and serum lipoprotein subclasses in the DCCT/EDIC cohort. Invest Ophthalmol Vis Sci. 2004;45:910–8.PubMedCrossRef Lyons TJ, Jenkins AJ, Zheng D, et al. Diabetic retinopathy and serum lipoprotein subclasses in the DCCT/EDIC cohort. Invest Ophthalmol Vis Sci. 2004;45:910–8.PubMedCrossRef
62.
go back to reference Simo R, Garcia-Ramirez M, Higuera M, Hernandez C. Apolipoprotein A1 is overexpressed in the retina of diabetic patients. Am J Ophthalmol. 2009;147:319–25. e311.PubMedCrossRef Simo R, Garcia-Ramirez M, Higuera M, Hernandez C. Apolipoprotein A1 is overexpressed in the retina of diabetic patients. Am J Ophthalmol. 2009;147:319–25. e311.PubMedCrossRef
63.
go back to reference Simó R, Higuera M, García-Ramírez M. Elevation of apolipoprotein A-I and apolipoprotein H levels in the vitreous fluid and overexpression in the retina of diabetic patients. Arch Ophthalmol. 2008;126:1076–81.PubMedCrossRef Simó R, Higuera M, García-Ramírez M. Elevation of apolipoprotein A-I and apolipoprotein H levels in the vitreous fluid and overexpression in the retina of diabetic patients. Arch Ophthalmol. 2008;126:1076–81.PubMedCrossRef
64.
go back to reference Wu M, Chen Y, Wilson K, et al. Intraretinal leakage and oxidation of LDL in diabetic retinopathy. Invest Ophthalmol Vis Sci. 2008;49:2679–85.PubMedCrossRef Wu M, Chen Y, Wilson K, et al. Intraretinal leakage and oxidation of LDL in diabetic retinopathy. Invest Ophthalmol Vis Sci. 2008;49:2679–85.PubMedCrossRef
65.
go back to reference Davidson MH. Apolipoprotein measurements: is more widespread use clinically indicated? Clin Cardiol. 2009;32:482–6.PubMedCrossRef Davidson MH. Apolipoprotein measurements: is more widespread use clinically indicated? Clin Cardiol. 2009;32:482–6.PubMedCrossRef
66.
go back to reference Sasongko MB, Wong TY, Nguyen TT, et al. Serum apolipoprotein AI and B are stronger biomarkers of diabetic retinopathy than traditional lipids. Diabetes Care. 2011;34:474–79.PubMedCrossRef Sasongko MB, Wong TY, Nguyen TT, et al. Serum apolipoprotein AI and B are stronger biomarkers of diabetic retinopathy than traditional lipids. Diabetes Care. 2011;34:474–79.PubMedCrossRef
67.
68.
go back to reference Rangasamy S, McGuire PG, Das A. Diabetic retinopathy and inflammation: novel therapeutic targets. Middle East Afr J Ophthalmol. 2012;19:52–9.PubMedCrossRef Rangasamy S, McGuire PG, Das A. Diabetic retinopathy and inflammation: novel therapeutic targets. Middle East Afr J Ophthalmol. 2012;19:52–9.PubMedCrossRef
69.
go back to reference Schram MT, Chaturvedi N, Schalkwijk CG, et al. Markers of inflammation are cross-sectionally associated with microvascular complications and cardiovascular disease in type 1 diabetes—the EURODIAB Prospective Complications Study. Diabetologia. 2005;48:370–78.PubMedCrossRef Schram MT, Chaturvedi N, Schalkwijk CG, et al. Markers of inflammation are cross-sectionally associated with microvascular complications and cardiovascular disease in type 1 diabetes—the EURODIAB Prospective Complications Study. Diabetologia. 2005;48:370–78.PubMedCrossRef
70.
go back to reference Nguyen TT, Alibrahim E, Amirul Islam F. Inflammatory, hemostatic and other novel biomarkers for diabetic retinopathy: The Multi-Ethnic Study of Atherosclerosis (MESA). Diabetes Care. 2009;32:1704–9.PubMedCrossRef Nguyen TT, Alibrahim E, Amirul Islam F. Inflammatory, hemostatic and other novel biomarkers for diabetic retinopathy: The Multi-Ethnic Study of Atherosclerosis (MESA). Diabetes Care. 2009;32:1704–9.PubMedCrossRef
71.
go back to reference Yilmaz T, Weaver CD, Gallagher MJ. Intravitreal triamcinolone acetonide injection for treatment of refractory diabetic macular edema: a systematic review. Ophthalmology. 2009;116:902–11. quiz 912–3.PubMedCrossRef Yilmaz T, Weaver CD, Gallagher MJ. Intravitreal triamcinolone acetonide injection for treatment of refractory diabetic macular edema: a systematic review. Ophthalmology. 2009;116:902–11. quiz 912–3.PubMedCrossRef
72.
go back to reference Beck RW, Edwards AR, Aiello LP, et al. Diabetic Retinopathy Clinical Research Network (DRCR.net) Three-year follow-up of a randomized trial comparing focal/grid photocoagulation and intravitreal triamcinolone for diabetic macular edema. Arch Ophthalmol. 2009;127:245–51.PubMedCrossRef Beck RW, Edwards AR, Aiello LP, et al. Diabetic Retinopathy Clinical Research Network (DRCR.net) Three-year follow-up of a randomized trial comparing focal/grid photocoagulation and intravitreal triamcinolone for diabetic macular edema. Arch Ophthalmol. 2009;127:245–51.PubMedCrossRef
73.
go back to reference Elman MJ, Aiello LP, Beck RW, et al. Diabetic Retinopathy Clinical Research Network. Randomized trial evaluating ranibizumab plus prompt or deferred laser or triamcinolone plus prompt laser for diabetic macular edema. (e35). Ophthalmology. 2010;117:1064–77.PubMedCrossRef Elman MJ, Aiello LP, Beck RW, et al. Diabetic Retinopathy Clinical Research Network. Randomized trial evaluating ranibizumab plus prompt or deferred laser or triamcinolone plus prompt laser for diabetic macular edema. (e35). Ophthalmology. 2010;117:1064–77.PubMedCrossRef
74.
go back to reference Elman MJ, Bressler NM, Qin H, et al. Expanded 2-year follow-up of ranibizumab plus prompt or deferred laser or triamcinolone plus prompt laser for diabetic macular edema. Ophthalmology. 2011;118:609–14.PubMedCrossRef Elman MJ, Bressler NM, Qin H, et al. Expanded 2-year follow-up of ranibizumab plus prompt or deferred laser or triamcinolone plus prompt laser for diabetic macular edema. Ophthalmology. 2011;118:609–14.PubMedCrossRef
75.
go back to reference Diabetic Retinopathy Clinical Research Network. A randomized trial comparing intravitreal triamcinolone acetonide and focal/grid photocoagulation for diabetic macular edema. (e1-10). Ophthalmology. 2008;115:1447–9.CrossRef Diabetic Retinopathy Clinical Research Network. A randomized trial comparing intravitreal triamcinolone acetonide and focal/grid photocoagulation for diabetic macular edema. (e1-10). Ophthalmology. 2008;115:1447–9.CrossRef
76.
go back to reference Ip MS, Bressler SB, Antoszyk AN, et al. A randomized trial comparing intravitreal triamcinolone and focal/grid photocoagulation for diabetic macular edema: Baseline features. Retina. 2008;28:919–30.PubMedCrossRef Ip MS, Bressler SB, Antoszyk AN, et al. A randomized trial comparing intravitreal triamcinolone and focal/grid photocoagulation for diabetic macular edema: Baseline features. Retina. 2008;28:919–30.PubMedCrossRef
77.
go back to reference Massin P, Bandello F, Garweg JG, et al. Safety and efficacy of ranibizumab in diabetic macular edema (RESOLVE Study): a 12-month, randomized, controlled, double-masked, multicenter phase II study. Diabetes Care. 2010;33:2399–405.PubMedCrossRef Massin P, Bandello F, Garweg JG, et al. Safety and efficacy of ranibizumab in diabetic macular edema (RESOLVE Study): a 12-month, randomized, controlled, double-masked, multicenter phase II study. Diabetes Care. 2010;33:2399–405.PubMedCrossRef
78.
go back to reference Nguyen QD, Brown DM, Marcus DM, et al. Ranibizumab for Diabetic Macular Edema: Results from 2 Phase III Randomized Trials: RISE and RIDE. Ophthalmology. 2012;119:789–801.PubMedCrossRef Nguyen QD, Brown DM, Marcus DM, et al. Ranibizumab for Diabetic Macular Edema: Results from 2 Phase III Randomized Trials: RISE and RIDE. Ophthalmology. 2012;119:789–801.PubMedCrossRef
79.
go back to reference Mitchell P, Bandello F, Schmidt-Erfurth U, et al. The RESTORE study: Ranibizumab monotherapy or combined with laser versus laser monotherapy for diabetic macular edema. Ophthalmology. 2011;118:615–25.PubMedCrossRef Mitchell P, Bandello F, Schmidt-Erfurth U, et al. The RESTORE study: Ranibizumab monotherapy or combined with laser versus laser monotherapy for diabetic macular edema. Ophthalmology. 2011;118:615–25.PubMedCrossRef
80.
go back to reference Liew G, Klein R, Wong TY. The role of genetics in susceptibility to diabetic retinopathy. Int Ophthalmol Clin. 2009;49:35–52.PubMedCrossRef Liew G, Klein R, Wong TY. The role of genetics in susceptibility to diabetic retinopathy. Int Ophthalmol Clin. 2009;49:35–52.PubMedCrossRef
81.
go back to reference Hallman DM, Huber Jr JC, Gonzalez VH, et al. Familial aggregation of severity of diabetic retinopathy in Mexican Americans from Starr County, Texas. Diabetes Care. 2005;28:1163–8.PubMedCrossRef Hallman DM, Huber Jr JC, Gonzalez VH, et al. Familial aggregation of severity of diabetic retinopathy in Mexican Americans from Starr County, Texas. Diabetes Care. 2005;28:1163–8.PubMedCrossRef
82.
go back to reference The Diabetes Control and Complications Trial Research Group. Clustering of long-term complications in families with diabetes in the diabetes control and complications trial. Diabetes. 1997;46:1829–39.CrossRef The Diabetes Control and Complications Trial Research Group. Clustering of long-term complications in families with diabetes in the diabetes control and complications trial. Diabetes. 1997;46:1829–39.CrossRef
83.
go back to reference Hietala K, Forsblom C, Summanen P, Groop PH. Heritability of proliferative diabetic retinopathy. Diabetes. 2008;57:2176–80.PubMedCrossRef Hietala K, Forsblom C, Summanen P, Groop PH. Heritability of proliferative diabetic retinopathy. Diabetes. 2008;57:2176–80.PubMedCrossRef
84.
go back to reference Arar NH, Freedman BI, Adler SG, et al. Heritability of the severity of diabetic retinopathy: the FIND-Eye study. Invest Ophthalmol Vis Sci. 2008;49:3839–45.PubMedCrossRef Arar NH, Freedman BI, Adler SG, et al. Heritability of the severity of diabetic retinopathy: the FIND-Eye study. Invest Ophthalmol Vis Sci. 2008;49:3839–45.PubMedCrossRef
85.
go back to reference Abhary S, Hewitt AW, Burdon KP, Craig JE. A systematic meta-analysis of genetic association studies for diabetic retinopathy. Diabetes. 2009;58:2137–47.PubMedCrossRef Abhary S, Hewitt AW, Burdon KP, Craig JE. A systematic meta-analysis of genetic association studies for diabetic retinopathy. Diabetes. 2009;58:2137–47.PubMedCrossRef
86.
go back to reference Sobrin L, Green T, Sim X, et al. Candidate gene association study for diabetic retinopathy in persons with type 2 diabetes: the Candidate gene Association Resource (CARe). Invest Ophthalmol Vis Sci. 2011;52:7593–602.PubMedCrossRef Sobrin L, Green T, Sim X, et al. Candidate gene association study for diabetic retinopathy in persons with type 2 diabetes: the Candidate gene Association Resource (CARe). Invest Ophthalmol Vis Sci. 2011;52:7593–602.PubMedCrossRef
87.
go back to reference Grassi MA, Tikhomirov A, Ramalingam S. Genome-wide meta-analysis for severe diabetic retinopathy. Hum Mol Genet. 2011;20:2472–81.PubMedCrossRef Grassi MA, Tikhomirov A, Ramalingam S. Genome-wide meta-analysis for severe diabetic retinopathy. Hum Mol Genet. 2011;20:2472–81.PubMedCrossRef
88.
go back to reference Grassi MA, Tikhomirov A, Ramalingam S, et al. Replication analysis for severe diabetic retinopathy. Invest Ophthalmol Vis Sci. 2012 Mar 16. [Epub ahead of print] Grassi MA, Tikhomirov A, Ramalingam S, et al. Replication analysis for severe diabetic retinopathy. Invest Ophthalmol Vis Sci. 2012 Mar 16. [Epub ahead of print]
89.
go back to reference Thomas RL, Dunstan F, Luzio SD. Incidence of diabetic retinopathy in people with type 2 diabetes mellitus attendingthe Diabetic Retinopathy Screening Service for Wales: retrospective analysis. BMJ. 2012;344:e874. doi:10.1136/bmj.e874.PubMedCrossRef Thomas RL, Dunstan F, Luzio SD. Incidence of diabetic retinopathy in people with type 2 diabetes mellitus attendingthe Diabetic Retinopathy Screening Service for Wales: retrospective analysis. BMJ. 2012;344:e874. doi:10.​1136/​bmj.​e874.PubMedCrossRef
90.
go back to reference Younis N, Broadbent DM, Vora JP, Harding SP. Liverpool Diabetic Eye Study. Incidence of sight-threatening retinopathy in patients with type 2 diabetes in the Liverpool Diabetic Eye Study: a cohort study. Lancet. 2003;361:195–200.PubMedCrossRef Younis N, Broadbent DM, Vora JP, Harding SP. Liverpool Diabetic Eye Study. Incidence of sight-threatening retinopathy in patients with type 2 diabetes in the Liverpool Diabetic Eye Study: a cohort study. Lancet. 2003;361:195–200.PubMedCrossRef
Metadata
Title
Current Epidemiology of Diabetic Retinopathy and Diabetic Macular Edema
Authors
Jie Ding
Tien Yin Wong
Publication date
01-08-2012
Publisher
Current Science Inc.
Published in
Current Diabetes Reports / Issue 4/2012
Print ISSN: 1534-4827
Electronic ISSN: 1539-0829
DOI
https://doi.org/10.1007/s11892-012-0283-6

Other articles of this Issue 4/2012

Current Diabetes Reports 4/2012 Go to the issue

Microvascular Complications—Retinopathy (JK Sun, Section Editor)

Novel Targets Against Retinal Angiogenesis in Diabetic Retinopathy

Microvascular Complications—Neuropathy (D Ziegler, Section Editor)

Management of Painful Diabetic Neuropathy: Guideline Guidance or Jungle?

Microvascular Complications—Nephropathy (B Roshan, Section Editor)

Insights into the Genetic Architecture of Diabetic Nephropathy

Microvascular Complications—Neuropathy (D Ziegler, Section Editor)

Neuropathic Pain: Is Quantitative Sensory Testing Helpful?

Microvascular Complications—Retinopathy (JK Sun, Section Editor)

Corticosteroid Use for Diabetic Macular Edema: Old Fad or New Trend?